In last trading session, Dianthus Therapeutics Inc (NASDAQ:DNTH) saw 0.3 million shares changing hands with its beta currently measuring 1.83. Company’s recent per share price level of $23.67 trading at -$0.03 or -0.13% at ring of the bell on the day assigns it a market valuation of $700.56M. That closing price of DNTH’s stock is at a discount of -42.67% from its 52-week high price of $33.77 and is indicating a premium of 22.52% from its 52-week low price of $18.34.
For Dianthus Therapeutics Inc (DNTH), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.17. Splitting up the data highlights that, out of 6 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.76 in the current quarter.
Dianthus Therapeutics Inc (NASDAQ:DNTH) trade information
Upright in the red during last session for losing -0.13%, in the last five days DNTH remained trading in the red while hitting it’s week-highest on Friday, 02/14/25 when the stock touched $23.67 price level, adding 6.99% to its value on the day. Dianthus Therapeutics Inc’s shares saw a change of 8.58% in year-to-date performance and have moved -1.91% in past 5-day. Dianthus Therapeutics Inc (NASDAQ:DNTH) showed a performance of 4.46% in past 30-days.
Wall Street analysts have assigned a consensus price target of 52 to the stock, which implies a rise of 54.48% to its current value. Analysts have been projecting 52 as a low price target for the stock while placing it at a high target of 52. It follows that stock’s current price would drop -119.69% in reaching the projected high whereas dropping to the targeted low would mean a loss of -119.69% for stock’s current value.
Dianthus Therapeutics Inc (DNTH) estimates and forecasts
This year revenue growth is estimated to rise 91.28% from the last financial year’s standing.
10 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 859.7k for the same. And 7 analysts are in estimates of company making revenue of 796k in the next quarter. Company posted 457k and 874k of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 29.95% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 69.69% while estimates for its earnings growth in next 5 years are of 23.64%.
On the other hand, Fidelity Growth Company Fund and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 933.52 shares of worth $22.1 million or 3.15% of the total outstanding shares. The later fund manager was in possession of 789.09 shares on Sep 30, 2024 , making its stake of worth around $18.68 million in the company or a holder of 2.67% of company’s stock.
